MD Anderson Ousts 3 Scientists Amid Concerns China is Trying to Steal Scientific Research

                                                                                          Issue # 2920 | April 23rd, 2019      





Advertisement

























Advertisement

























Advertisement

























Advertisement

























Advertisement
























Advertisement
























Advertisement
  
News Alert



MD Anderson Ousts 3 Scientists Amid Concerns China is Trying to Steal Scientific Research

MD Anderson Cancer Center is ousting three scientists in connection with concerns China is trying to steal U.S. scientific research, the first such publicly disclosed punishments since federal officials directed some institutions to investigate specific professors in violation of granting agency policies. This comes after the center received e-mails last year from the NIH describing conflicts of interest or unreported foreign income by five faculty members. MD Anderson's action comes amid heightened concern that China and others are exploiting U.S.-funded research for their own benefit, enlisting students and visiting scholars to pilfer intellectual property, luring scientists to run "shadow laboratories" in their countries. Learn More




Lilly Investing $35 Million Upfront to Partner with Avidity

This week Lilly announced a deal with Avidity Biosciences aimed at finding treatments for immunological diseases and other "select" indications by deploying the latter company's antibody oligonucleotide conjugate platform - which, as its name suggests, combines monoclonal antibodies with oligonucleotide-based therapies. Lilly is investing $15 million in its new partner in addition to a $20 million upfront payment. Avidity could take home around $405 million in milestone payments per development target, as well as tiered royalties in the mid-single to low-double digit range should any product resulting from the collaboration make it to market. Learn More
 



BI Keen on Crossing Animal Health Innovation with Human BioPharma

Boehringer Ingelheim (BI), which is present in both human and animal health, has made public its plans for the potential of innovation in animal health where it crosses over with human pharma. Company Chairman Hubertus von Baumbach, speaking on the subject at the companies HQ, shared that the company was stepping up the level of exchange between human and animal health. "We are convinced that we will in the future learn increasingly from one another in R&D," he said adding that this form of synergy could not be quantified today but as one of the few remaining companies with such a profile, Boehringer sees a distinct strategic advantage. Learn More

Advertisement
Quote Alert


On this Day Alert

1987 Chrysler Buys Lamborghini


Although the terms of the deal were not disclosed, the media reported that Chrysler paid $25 million for Lamborghini, which at the time was experiencing financial difficulties. Today, Lamborghini is owned by Volkswagen. Learn More

Advertisement
TED Alert

The Secret to Great Opportunities? The Person You Haven't Met Yet


We often find ourselves stuck in narrow social circles with similar people. What habits confine us, and how can we break them? Organizational psychologist Tanya Menon considers how we can be more intentional about expanding our social universes -- and how it can lead to new ideas and opportunities. Learn More

Poll Alert